Pumitamig (BNT327, PD-L1xVEGF Bispecific)
Small cell and non-small cell lung cancer, triple-negative breast cancer
Sponsor: BioNTech
- 4,300Enrollment target
- N/ATrial sites
- N/ACountries
- December 2028Est. completion
- NCT07173751Registry record
About this trial
Partnered with Bristol Myers Squibb. PD-L1xVEGF bispecifics are the most contested class in oncology after the ivonescimab debate, and this is BioNTech’s largest value driver.
Primary endpoints
- Progression-free survival
- Overall survival
Latest update
BioNTech and Bristol Myers Squibb reported encouraging interim data for pumitamig with chemotherapy in first-line lung cancer around ASCO 2026, and BioNTech highlighted late-stage lung-cancer momentum and first global data for a pumitamig plus elfetabart drozuntecan combination in August.
SourceTrial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.